PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation clinical oncology sequencing company, today announced a partnership that will allow Pillar Biosciences to directly sell clinical genomics reports of PierianDx in combination with its cancer profiling tests. Under the terms of the agreement, PierianDx will integrate the PiVAT® bioinformatics pipeline from Pillar Biosciences into the PierianDx environment to provide users with fast-track implementation, as well as test-specific variant filters, to produce the test reports. Best-in-class clinical genomics, providing a complete solution from sample to response.

Laboratories around the world use Pillar Biosciences tests to detect pivotal genetic variants of cancer and other diseases. Pillar Biosciences' targeted panels rely on a proprietary enrichment chemistry, SLIMamp®, which enables rapid and automated amplicons in a single tube from minimal sampling. Pillar Biosciences' complementary bioinformatics pipeline, PiVAT ®, is optimized for efficiency, reducing reflex testing and offering a low frequency variant that can detect every type of variant while consuming little computing resources. PierianDx provides the Clinical Genomics Workspace ™, which consists of intuitive software and a strong clinical knowledge base. This software turns variant information into a highly structured and comprehensive report ready for the physician to use.

Rationalization of the NSE, clinical genomic interpretation and reporting remain long and difficult, especially when it comes to sophisticated panels. By combining the Pillar Biosciences panels with the PierianDx reports, a very in-depth and optimized clinical genomic report will be obtained for each test. In addition, the solution will be available to customers worldwide via secure cloud instances and, in the case of European regions, compliant with the General Data Protection Regulation (GDPR). As a result, laboratories and healthcare organizations around the world will have a highly reliable method to deliver these tests, which will make high-precision diagnostics and treatment possible for their patients.

“Pillar Biosciences testing provides robust detection for all types of variants within a streamlined workflow,” said Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating them into the PiVAT pipeline, PierianDx streamlines interpretation and reporting, allowing our customers to benefit from substantial additional value. "

Rakesh Nagarajan, MD, PhD and Founder, CTO and Visionary of PierianDx, added: “We are delighted to provide this support for Pillar Biosciences testing. As the market shifts to more sensitive assays in the TDL space and major assay manufacturers seek in vitro diagnostic (IVD) approval , we are determined to address the challenges that arise from even greater complexity. great in the process of interpretation and reporting. "

About PierianDx

Founded in 2014 at Washington University in St. Louis, PierianDx's mission is to advance cancer diagnosis and make targeted therapies more accessible to healthcare systems, laboratories and patients around the world. Its state-of-the-art clinical genomics technologies, College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory, DVI-ready knowledge base and reporting solution, and expertise provide the most effective approach. most integrated, most reliable and most collaborative in the entire field of clinical care. From genomic sequencing and biomedical computing in the lab to reporting and decision support at the bedside,www.pieriandx.com

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automable variant detection technologies deliver robust results with fast turnaround times through streamlined SNG workflows. Based on SLIMamp ® and PiVAT ® , our products help high throughput reference laboratories and clinical oncology laboratories to streamline precision medicine by increasing their diagnostic productivity.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared to the source text, which will set a precedent.

Contacts
Media contact for PierianDx:
Garreth Hippe
info@pieriandx.com

Media contact for Pillar Biosciences:
William Wright
info@pillar-biosciences.com

 

Source: businesswire.com

Report Abuse